Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Current Quarter	$-0.06	Next Quarter	$NA
Current Year	$-0.27	Next Year	$-0.41
QoQ Growth	NaN%	YoY Growth	-51.9%
3Y EPS CAGR	+17.1%	Target Price	$3.33
Consensus	Buy	Upside	+813.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VXRT	$0.36	-3.29%	353.87K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VXRT	$0.36	-3.3%	353.87K
3
4
5
6

VXRT

VXRT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Vaxart Inc. Data in Excel

Get Vaxart Inc. Data in Excel